Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

205 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Assessment of residual tumour by FDG-PET: conventional imaging and clinical examination following primary chemotherapy of large and locally advanced breast cancer.
Dose-Schwarz J, Tiling R, Avril-Sassen S, Mahner S, Lebeau A, Weber C, Schwaiger M, Jänicke F, Untch M, Avril N. Dose-Schwarz J, et al. Among authors: lebeau a. Br J Cancer. 2010 Jan 5;102(1):35-41. doi: 10.1038/sj.bjc.6605427. Epub 2009 Nov 17. Br J Cancer. 2010. PMID: 19920815 Free PMC article. Clinical Trial.
Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with [18F]fluorodeoxyglucose.
Schwarz-Dose J, Untch M, Tiling R, Sassen S, Mahner S, Kahlert S, Harbeck N, Lebeau A, Brenner W, Schwaiger M, Jaenicke F, Avril N. Schwarz-Dose J, et al. Among authors: lebeau a. J Clin Oncol. 2009 Feb 1;27(4):535-41. doi: 10.1200/JCO.2008.17.2650. Epub 2008 Dec 15. J Clin Oncol. 2009. PMID: 19075273
PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin-cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast cancer--outcome on prognosis.
Untch M, von Minckwitz G, Konecny GE, Conrad U, Fett W, Kurzeder C, Lück HJ, Stickeler E, Urbaczyk H, Liedtke B, Beckmann MW, Salat C, Harbeck N, Müller V, Schmidt M, Hasmüller S, Lenhard M, Nekljudova V, Lebeau A, Loibl S, Fasching PA; Arbeitsgemeinschaft Gynäkologische Onkologie PREPARE investigators. Untch M, et al. Among authors: lebeau a. Ann Oncol. 2011 Sep;22(9):1999-2006. doi: 10.1093/annonc/mdq713. Epub 2011 Mar 7. Ann Oncol. 2011. PMID: 21382868 Free article. Clinical Trial.
8p deletion is strongly linked to poor prognosis in breast cancer.
Lebok P, Mittenzwei A, Kluth M, Özden C, Taskin B, Hussein K, Möller K, Hartmann A, Lebeau A, Witzel I, Mahner S, Wölber L, Jänicke F, Geist S, Paluchowski P, Wilke C, Heilenkötter U, Simon R, Sauter G, Terracciano L, Krech R, von der Assen A, Müller V, Burandt E. Lebok P, et al. Among authors: lebeau a. Cancer Biol Ther. 2015;16(7):1080-7. doi: 10.1080/15384047.2015.1046025. Epub 2015 May 11. Cancer Biol Ther. 2015. PMID: 25961141 Free PMC article.
Partial PTEN deletion is linked to poor prognosis in breast cancer.
Lebok P, Kopperschmidt V, Kluth M, Hube-Magg C, Özden C, B T, Hussein K, Mittenzwei A, Lebeau A, Witzel I, Wölber L, Mahner S, Jänicke F, Geist S, Paluchowski P, Wilke C, Heilenkötter U, Simon R, Sauter G, Terracciano L, Krech R, von d Assen A, Müller V, Burandt E. Lebok P, et al. Among authors: lebeau a. BMC Cancer. 2015 Dec 16;15:963. doi: 10.1186/s12885-015-1770-3. BMC Cancer. 2015. PMID: 26672755 Free PMC article.
Prognostic relevance of AIB1 (NCoA3) amplification and overexpression in breast cancer.
Burandt E, Jens G, Holst F, Jänicke F, Müller V, Quaas A, Choschzick M, Wilczak W, Terracciano L, Simon R, Sauter G, Lebeau A. Burandt E, et al. Among authors: lebeau a. Breast Cancer Res Treat. 2013 Feb;137(3):745-53. doi: 10.1007/s10549-013-2406-4. Epub 2013 Jan 16. Breast Cancer Res Treat. 2013. PMID: 23322234
Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer.
Untch M, Möbus V, Kuhn W, Muck BR, Thomssen C, Bauerfeind I, Harbeck N, Werner C, Lebeau A, Schneeweiss A, Kahlert S, von Koch F, Petry KU, Wallwiener D, Kreienberg R, Albert US, Lück HJ, Hinke A, Jänicke F, Konecny GE. Untch M, et al. Among authors: lebeau a. J Clin Oncol. 2009 Jun 20;27(18):2938-45. doi: 10.1200/JCO.2008.20.3133. Epub 2009 Apr 13. J Clin Oncol. 2009. PMID: 19364964 Clinical Trial.
Assessing HER2 testing quality in breast cancer: variables that influence HER2 positivity rate from a large, multicenter, observational study in Germany.
Rüschoff J, Lebeau A, Kreipe H, Sinn P, Gerharz CD, Koch W, Morris S, Ammann J, Untch M; Nicht-interventionelle Untersuchung (NIU) HER2 Study Group. Rüschoff J, et al. Among authors: lebeau a. Mod Pathol. 2017 Feb;30(2):217-226. doi: 10.1038/modpathol.2016.164. Epub 2016 Oct 21. Mod Pathol. 2017. PMID: 27767099 Free article.
Gene amplification in ductal carcinoma in situ of the breast.
Burkhardt L, Grob TJ, Hermann I, Burandt E, Choschzick M, Jänicke F, Müller V, Bokemeyer C, Simon R, Sauter G, Wilczak W, Lebeau A. Burkhardt L, et al. Among authors: lebeau a. Breast Cancer Res Treat. 2010 Oct;123(3):757-65. doi: 10.1007/s10549-009-0675-8. Epub 2009 Dec 22. Breast Cancer Res Treat. 2010. PMID: 20033484
PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin/cyclophosphamide followed by paclitaxel ± darbepoetin alfa in primary breast cancer--results at the time of surgery.
Untch M, Fasching PA, Konecny GE, von Koch F, Conrad U, Fett W, Kurzeder C, Lück HJ, Stickeler E, Urbaczyk H, Liedtke B, Salat C, Harbeck N, Müller V, Schmidt M, Hasmüller S, Lenhard M, Schuster T, Nekljudova V, Lebeau A, Loibl S, von Minckwitz G; Arbeitsgemeinschaft Gynäkologische Onkologie PREPARE investigators. Untch M, et al. Among authors: lebeau a. Ann Oncol. 2011 Sep;22(9):1988-1998. doi: 10.1093/annonc/mdq709. Epub 2011 Mar 8. Ann Oncol. 2011. PMID: 21385882 Free article. Clinical Trial.
205 results